1. Rodon J., …, Saintigny P., …, Kurzrock R. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019 May;25(5):751-758.
2. Foy JP., Bertolus C., Ortiz-Cuaran S., Albaret MA., …, Destandau S., Souza G., …, Saintigny P. Immunological and classical subtypes of oral premalignant lesions. Oncoimmunology. 2018 Sep 21;7(12):e1496880.
3. Albaret MA., …, Paré A., …, Saintigny P., Diaz JJ. Externalized Keratin 8: A Target at the Interface of Microenvironment and Intracellular Signaling in Colorectal Cancer Cells. Cancers (Basel). 2018 Nov 16;10(11). pii: E452.
4. Saintigny P., Mitani Y., Pytynia KB., Ferrarotto R., Roberts DB., Weber RS., Kies MS., Maity SN., Lin SH., El-Naggar AK. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer. 2018 Sep 15;124(18):3693-3705.
5. Saintigny P., William WN Jr., Foy JP., Papadimitrakopoulou V., Lang W., Zhang L., Fan YH., Feng L., Kim ES., El-Naggar AK., Lee JJ., Mao L., Hong WK., Lingen MW., Lippman SM. Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. J Natl Cancer Inst. 2018 Mar 1;110(3).
6. Martinez P., Mallo D., Paulson TG., Li X., Sanchez CA., Reid BJ., Graham TA., Kuhner MK., Maley CC. Evolution of Barrett’s esophagus through space and time at single-crypt and whole-biopsy levels. Nat Commun. 2018;9(1):794.
7. Foy JP., Bazire L., Ortiz-Cuaran S., Deneuve S., Kielbassa J., Thomas E., Viari A., Puisieux A., Goudot P., Bertolus C., Foray N., Kirova Y., Verrelle P., Saintigny P. A13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes. BMC Med. 2017 Sep 1;15(1):165.
8. Foy JP., Bertolus C., …, Albaret MA., Ortiz-Cuaran S., …, Fayette J., …, Zrounba P., …, Saintigny P. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade. Ann Oncol. 2017 Aug 1;28(8):1934-1941.
9. Morel AP …, Saintigny P …, Puisieux A. A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability. Nat Med. 2017 May;23(5):568-578.
10. Ferrari A., …, Saintigny P., Birnbaum D., Viari A., Thomas G. A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. Nat Commun. 2016 Jul 13;7:12222.
11. Timmer MR*., Martinez P.,*…., Derivation of genetic biomarkers for cancer risk stratification in Barrett's Oesophagus: a prospective cohort study. Gut, 2016 Oct;65(10):1602-10.
12. Ortiz-Cuaran S*., …., Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clin Cancer Res. 2016 Oct 1;22(19):4837-4847.
13. Martinez P., ..., Dynamic clonal equilibrium and predetermined cancer risk in Barrett’s oesophagus. Nat Commun. 2016;7:12158.
14. Lavery DL., Martinez P., Gay LJ., Cereser B., Novelli MR., Rodriguez-Justo M., ... Jansen M. Evolution of oesophageal adenocarcinoma from metaplastic columnar epithelium without goblet cells in Barrett's oesophagus. Gut, 2016;65(6):907-913.
15. Lavergne V., Harliwong I., Jones A., Miller D., Taft RJ., Alewood PF. Optimized deep-targeted proteotranscriptomic profiling reveals unexplored Conus toxin diversity and novel cysteine frameworks. Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):E3782-91.
16. Lovly CM., …, Ortiz-Cuaran S., …., Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med. 2014 Sep;20(9):1027-34.
17. Fernandez-Cuesta L*., Plenker D*., …, Ortiz-Cuaran S., …., CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov. 2014 Apr;4(4):415-22.
18. Gerlinger M., Horswell S., Larkin J., Rowan AJ., Salm MP., …Martinez P., …, Swanton C. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nature Genetics, 2014;46(3):225-233.